D0996 | methyldigoxin
C
C01AA08 Metildigoxin
[C01AA] Digitalis glycosides
[C01A] CARDIAC GLYCOSIDES
[C01] CARDIAC THERAPY
[C] Cardiovascular system
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 0.73±0.09 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 0.24 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
    |
Danger |
Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral] H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H330 (50%): Fatal if inhaled [Danger Acute toxicity, inhalation] H331 (50%): Toxic if inhaled [Danger Acute toxicity, inhalation] H372 (50%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] H400 (50%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard] H410 (50%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] H412 (50%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P260, P261, P264, P270, P271, P273, P280, P284, P301+P310, P304+P340, P305+P351+P338, P310, P311, P314, P320, P321, P330, P337+P313, P391, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| rat | LD50 | subcutaneous | 5930ug/kg (5.93mg/kg) | Yakkyoku. Pharmacy. Vol. 31, Pg. 1127, 1980. | |
| mouse | LD50 | oral | 7350mg/kg (7350mg/kg) | Yaoxue Tongbao. Bulletin of Pharmacology. Vol. 18, Pg. 404, 1983. | |
| rabbit | LD50 | oral | 5900ug/kg (5.9mg/kg) | Medicamentos de Actualidad. Vol. 12, Pg. 319, 1976. | |
| guinea pig | LDLo | intravenous | 653ug/kg (0.653mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 28, Pg. 495, 1978. | |
| rat | LD50 | oral | 8300ug/kg (8.3mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 231, 1971. | |
| rat | LD50 | intraperitoneal | 6200ug/kg (6.2mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 231, 1971. | |
| cat | LDLo | intravenous | 190ug/kg (0.19mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 28, Pg. 495, 1978. | |
| man | LDLo | intravenous | 160ug/kg (0.16mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 34, Pg. 769, 1984. | |
| pigeon | LDLo | unreported | 588ug/kg (0.588mg/kg) | Yaoxue Tongbao. Bulletin of Pharmacology. Vol. 16(7), Pg. 60, 1981. | |
| mouse | LD50 | intravenous | 4900ug/kg (4.9mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 231, 1971. | |
| rat | LD50 | intravenous | 4800ug/kg (4.8mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 231, 1971. | |
| guinea pig | LD50 | intraduodenal | 1550ug/kg (1.55mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 225, 1971. | |
| cat | LDLo | intraduodenal | 455ug/kg (0.455mg/kg) | cardiac: cardiomyopathy including infarction | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 225, 1971. |
| pigeon | LDLo | intravenous | 453ug/kg (0.453mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 225, 1971. | |
| mouse | LD50 | subcutaneous | 9390ug/kg (9.39mg/kg) | Drugs in Japan Vol. 6, Pg. 828, 1982. | |
| mouse | LD50 | intraperitoneal | 4800ug/kg (4.8mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 231, 1971. | |
| guinea pig | LD50 | intraperitoneal | 800ug/kg (0.8mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 373, 1973. | |
| guinea pig | LD50 | oral | 2100ug/kg (2.1mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 373, 1973. | |
| (3beta,5beta,12beta)-3-{[2,6-dideoxy-4-O-methyl-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; | 30685-43-9 | 4'''-Methyldigoxin |
| 4'''-O-Methyldigoxin | AKOS030242278 | BRN 1339127 |
| Betamethyl digoxin | CAS-30685-43-9 | CHEBI:135885 |
| CHEMBL1697843 | CTK8G3982 | Card-20(22)-enolide, 3-((O-2,6-dideoxy-4-O-methyl-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3-beta,5-beta,12-beta)- |
| D09847 | DB13401 | DSSTox_CID_3294 |
| DSSTox_GSID_23294 | DSSTox_RID_76961 | DTXSID0023294 |
| Digoxin, 4'''-O-methyl- | EINECS 250-292-0 | FT-0628872 |
| I7GG1YUC5V | IYJMSDVSVHDVGT-PEQKVOOWSA-N | Lanitop |
| MEDIGOXIN | Medigossina | Medigossina [DCIT] |
| Medigoxin (BAN) | Medigoxina | Medigoxina [Spanish] |
| Methyldigoxin | Metildigoxin (INN) | Metildigoxin [INN:BAN:JAN] |
| Metildigoxina | Metildigoxina [INN-Spanish] | Metildigoxine |
| Metildigoxine [INN-French] | Metildigoxinum | Metildigoxinum [INN-Latin] |
| NCGC00168746-01 | Q550017 | SCHEMBL43349 |
| Tox21_112625 | UNII-I7GG1YUC5V | ZINC254011770 |
| beta-Methyl Digoxin | beta-Methyldigoxin | beta-Metildigoxina |
| beta-Metildigoxina [Spanish] | metildigoxin |